{"prompt": "['Cara Therapeutics, Inc.', 'Difelikefalin (IV CR845)', 'CR845-CLIN3102', 'Clinical Study Report - Double-blind Phase', 'Cara Therapeutics Inc.', 'Confidential', 'Page 16 of 92', 'CR845-CLIN3102', '6.4.2.1', 'Formulation of Study Drug', '36', '6.4.2.2', 'Packaging, Labeling, and Storage Stability of Study Drug', '37', '6.4.2.3', 'Individual Dose Labeling', '38', '6.4.3', 'Drug Accountability', '38', '6.4.4', 'Method of Assigning Patients to Treatment Groups', '38', '6.4.5', 'Preparation of CR845', '38', '6.4.6', 'Management of Missed Doses', '39', '6.4.7', 'Treatment Compliance', '39', '6.4.8', 'Blinding', '39', '6.4.9', 'Prior, Concomitant, and Prohibited Medications', '39', '6.4.9.1', 'Prior and Concomitant Medications', '39', '6.4.9.2', 'Restricted and Prohibited Medications', '39', '6.5', 'Study Assessments and Procedures', '40', '6.5.1', 'Schedule of Events for the Double-blind Phase', '40', '6.5.2', 'Schedule of Events for the Open-label Extension Phase', '44', '6.5.3', 'Efficacy Assessments', '48', '6.5.3.1', 'Worst Itching Intensity Numerical Rating Scale', '48', '6.5.3.2', 'Skindex-10 Scale', '48', '6.5.3.3', '5-D Itch Scale', '48', '6.5.3.4', 'Patient Global Impression of Change', '49', '6.5.4', 'Safety Assessments', '49', '6.5.4.1', 'Adverse Events', '49', '6.5.4.2', 'Structured Safety Evaluation', '53', '6.5.4.3', 'Physical Examination', '53', '6.5.4.4', 'Vital Signs', '54', '6.5.4.5', 'Electrocardiogram', '54', '6.5.4.6', 'Clinical Laboratory Tests', '54', '6.5.4.7', 'Contraception and Pregnancy', '54', '6.5.5', 'Additional Assessments', '55', '6.5.5.1', 'Inflammatory Biomarkers', '55', '6.5.5.2', 'Missed Dialysis Visits', '56', '21 December 2017', 'Version 1.0', 'CONFIDENTIAL', 'Page 18 of 95']['Cara Therapeutics, Inc.', 'Difelikefalin (IV CR845)', 'CR845-CLIN3102', 'Clinical Study Report - Double-blind Phase', 'Cara Therapeutics Inc.', 'Confidential', 'Page 17 of 92', 'CR845-CLIN3102', '6.5.5.3', 'ESAs and IV Iron', '56', '6.5.5.4', 'Discontinuation Period Additional Assessments', '56', '7.0 Discussion and Justification of Study Design', '57', '7.1', 'Discussion of Study Design and Choice of Control Groups', '57', '7.2', 'Selection of Doses in the Study', '57', '7.3', 'Appropriateness of Measurements', '57', '8.0 Statistical Methods', '58', '8.1', 'General Considerations', '58', '8.2', 'Determination of Sample Size', '58', '8.3', 'Randomization', '59', '8.4', 'Interim Analysis', '60', '8.4.1', 'Sample Size Re-estimation', '60', '8.4.2', 'Safety Data Review', '61', '8.5', 'Analysis Populations', '61', '8.6', 'Statistical Summary and Analysis', '62', '8.6.1', 'Patient Disposition', '62', '8.6.2', 'Protocol Deviations', '62', '8.6.3', 'Demographic and Baseline Characteristics', '62', '8.6.4', 'Medical History', '62', '8.6.5', 'Prior and Concomitant Medications', '63', '8.6.6', 'Antipruritic Medication', '63', '8.7', 'Efficacy Analysis', '63', '8.7.1', 'Primary Efficacy Endpoint', '63', '8.7.2', 'Secondary Efficacy Endpoints', '65', '8.7.3', 'Hypothesis Testing Strategy', '66', '8.7.4', 'Additional Efficacy Endpoints', '67', '8.7.4.1', 'Itch-intensity Measures', '67', '8.7.4.2', 'Itch-related Quality-of-Life Measures', '67', '8.8', 'Safety Analysis', '68', '8.8.1', 'Exposure to Study Drug', '68', '8.8.2', 'Adverse Events', '69', '21 December 2017', 'Version 1.0', 'CONFIDENTIAL', 'Page 19 of 95']\n\n###\n\n", "completion": "END"}